Prev: Vitamin D lecture
Next: Could Strontium Citrate Contain Strontium-90?
From: trigonometry1972 on 1 May 2008 03:18
Strontium ranelate reduces the risk of vertebral fractures
in patients with osteopenia.
Seeman E, Devogelaer JP, Lorenc R, Spector T,
Brixen K, Balogh A, Stucki G, Reginster JY.

Austin Health, University of
Melbourne, Australia. egos(a)unimelb.edu.au

Many fractures occur in women with moderate fracture
risk caused by osteopenia. Strontium ranelate was
studied in 1431 postmenopausal women with osteopenia.
Vertebral fracture risk reduction of 41-59% was
shown depending on the site and fracture status at
baseline. This is the first report of antivertebral
fracture efficacy in women with vertebral osteopenia.

INTRODUCTION:
Women with osteoporosis are at high risk
for fracture. However, more than one half of all
fractures in the community originate from the larger
population at more moderate risk of fracture caused by
osteopenia. Despite this, evidence for antifracture
efficacy in these persons is limited. The aim of this
study was to determine whether strontium ranelate,
a new drug that reduces fracture risk in women with o
steoporosis, is also effective in women with osteopenia.

MATERIALS AND METHODS:
Data from the Spinal Osteoporosis Therapeutic Intervention
study (SOTI; n = 1649) and the TReatment Of Peripheral
OSteoporosis (TROPOS; n = 5091) were pooled to evaluate
the antivertebral fracture efficacy of strontium ranelate
in women with lumbar spine (LS) osteopenia with any BMD
value at the femoral neck (FN; N = 1166) and in 265
women with osteopenia at both sites (intention-to-treat analysis).
The women were randomized to strontium ranelate 2 g/d orally
or placebo for 3 yr.

RESULTS:
No group differences were present
in baseline characteristics that may influence fracture
outcome independent of therapy. In women with LS osteopenia,
treatment reduced the risk of vertebral fracture by 41%
(RR = 0.59; 95% CI, 0.43-0.82), by
59% (RR = 0.41; 95% CI, 0.17-0.99) in the 447 patients
with no prevalent fractures, and
by 38% (RR = 0.62; 95% CI, 0.44-0.88) in the 719 patients
with prevalent fractures. In women with osteopenia at
both sites, treatment reduced the risk of fracture
by 52% (RR = 0.48; 95% CI, 0.24-0.96).

CONCLUSIONS:
Strontium ranelate safely reduces the risk of vertebral
fractures in women with osteopenia with or without a prevalent
fracture.

PMID: 17997711
From: trigonometry1972 on 1 May 2008 13:47
Sorry about the multiple postings, Google was behaving oddly last
night and it didn't seem to be accepting my postings.

More on the topic.




1: Aust Fam Physician. 2007 Aug;36(8):631-2.

Strontium ranelate--does it affect the management of postmenopausal
osteoporosis?

Winzenberg T, Powell S, Jones G.

Menzies Research Institute, University of Tasmania.
tania.winzenberg(a)utas.edu.au

This series of articles facilitated by the Cochrane
Musculoskeletal Group (CMSG) aims to place the findings
of recent Cochrane musculoskeletal reviews in a
context immediately relevant to general practitioners.
This article considers whether the availability of
strontium ranelate affects the management of
postmenopausal osteoporosis.


PMID: 17676187 [PubMed - indexed for MEDLINE]

Full article is available by way of a PUBMED link to site with no
charge for the article.
===================================

1: J Bone Miner Res. 2005 Sep;20(9):1569-78.
Epub 2005 Apr 27.

Long-term strontium ranelate administration in
monkeys preserves characteristics of bone mineral
crystals and degree of mineralization of bone.

Farlay D, Boivin G, Panczer G, Lalande A, Meunier PJ.

Laboratoire d'Histodynamique Osseuse,
Faculté de Médecine R. Laennec, Université
C. Bernard-Lyon 1, Lyon, France.

In monkeys, long-term strontium ranelate administration
results in a dose-dependent bone strontium uptake
(mainly into newly formed bone) that
preserves the degree of mineralization of bone
and the bone mineral at the crystal level,
showing its safety at bone mineral level.

INTRODUCTION:
Strontium ranelate simultaneously increases bone formation
and decreases bone resorption, leading to prevention of
bone loss and increase in bone mass and bone strength in
normal and ovariectomized rats. This study investigated
the interactions of stable strontium (Sr) with bone
mineral in monkeys after long-term strontium
ranelate treatment and after a period of treatment withdrawal.

MATERIALS AND METHODS:
Iliac bone was obtained from untreated monkeys, monkeys at
the end of a 52-week strontium ranelate administration
(200, 500, 1250 mg/kg/day orally), and in parallel
groups 10 weeks after the end of strontium ranelate
administration (same three doses; n = 3-7).
Sr uptake and distribution in bone mineral were
quantified by X-ray microanalysis, changes at the
crystal level by X-ray diffraction, and the degree of
mineralization of bone (DMB) by quantitative
microradiography.

RESULTS:
After strontium ranelate administration, dose-dependent
Sr uptake occurred into cortical and cancellous bone,
with higher content (1.6 times) in new than in old bone.
This Sr uptake decreased (50%) 10 weeks after treatment
withdrawal; the decrease occurred almost exclusively in new
bone. At the end of strontium ranelate treatment and after
its withdrawal, a preservation of crystal characteristics
was observed, suggesting that Sr was only
faintly linked to crystals by ionic substitution and of DMB.

CONCLUSIONS:
These results show the absence of a deleterious
effect of long-term strontium ranelate
treatment on bone mineralization, confirming
the histomorphometric observations made in postmenopausal
osteoporotic women treated with strontium ranelate.


PMID: 16059629 [PubMed - indexed for MEDLINE]

Related Links

The mineralization of bone tissue: a forgotten dimension in
osteoporosis
research. [Osteoporos Int. 2003] PMID:12730799

Strontium distribution and interactions with bone mineral in
monkey iliac bone
after strontium salt (S 12911) administration. [J Bone Miner Res.
1996]
PMID:8864905

Strontium ranelate improves bone resistance by increasing bone
mass and improving
architecture in intact female rats. [J Bone Miner Res. 2004] PMID:
15537445

Strontium ranelate in osteoporosis. [Curr Pharm Des. 2002] PMID:
12171530

Strontium ranelate inhibits bone resorption while maintaining bone
formation in
alveolar bone in monkeys (Macaca fascicularis). [Bone. 2001] PMID:
11502480
=====================

Final note:
Other salts other than ranelate of strontium worked in rodents.

From: Marshall Price on 3 May 2008 18:33
BoneLady wrote:
> On Apr 23, 1:36 pm, "trigonometry1...(a)gmail.com |"
> <trigonometry1...(a)gmail.com> wrote:
>>> On Apr 23, 8:51 am, BoneLady <srsuppor...(a)gmail.com> wrote:
>>> Are you interested in an alternative to prescription drugs for
>>> osteoporosis? Strontium builds stronger bones than drugs like Fosamax,
>>> Actonel, or Boniva but without the dangerous side effects. For more
>>> information about strontium for treating osteoporosis, please visit
>>> Strontium For Bones athttp://strontiumforbones.blogspot.com/. My
>>> blog offers visitors discussions, information, and links which will be
>>> updated periodically
>> The blog took too long download when I wanted to comment for impatient
>> me.
>
> Try being more patient. My blog has been tested on dial-up and only
> takes less than a minute to load on 50Kps service.

I found it surprising that strontium (atomic number 38, directly
below calcium in the periodic table) not only encourages osteoblasts and
discourages osteoclasts, but it also enters sufficiently into bone
mineralization to "confuse" the radiologists so they have to distinguish
between real bone "density" and the "density" caused by the greater
radio-opacity of strontium compared to calcium.

It makes me wonder how important strontium is in human nutrition, how
abundant it is, and whether it ought to be added to soils.

--
Marshall Price of Miami
Known to Yahoo as d021317c
From: Ron Peterson on 3 May 2008 18:36
On Apr 30, 7:26 pm, Bruce in Bangkok
<decypher_signat...(a)signature.line> wrote:
> On Wed, 30 Apr 2008 14:44:21 -0700 (PDT), Ron Peterson
>
>
>
> <r...(a)shell.core.com> wrote:
> >On Apr 24, 2:43 pm, BoneLady <srsuppor...(a)gmail.com> wrote:
> >> On Apr 23, 6:12 pm, Ron Peterson <r...(a)shell.core.com> wrote:
>
> >> > I don't believe that strontium is considered a nutrient and that makes
> >> > it difficult to recommend.
>
> >> Strontium is considered to be an essential nutrient like calcium and
> >> is available in small amounts from food. It is believed that the
> >> strontium-calcium bone matrix is far stronger than calcium matrix
> >> alone.
>
> >Who considers strontium to be an essential nutrient?
>
> >Is there a study that indicates that strontium in the bone matrix is
> >the cause of higher bone strength?
>
> The physician's information sheet packed with the Strontium Renelate I
> am taking includes some details of the studies made:
>
> Two placebo controlled phase III studies: SOTI and TROPOS study. SOTI
> involved 1,649 postmenopausal women with established osteoporosis (low
> lumber BMD and prevalent vertebral fracture) and a mean age of 70
> years....1,556 patients over 80 years at inclusion...reduced the
> relative risk of fracture by 41 % over 3 years in the SOTI study
> (table 1)...

Does the information sheet analyze why the drug reduces the relative
risk of fracture? Is it due to the strontium in the bone matrix?

--
Ron

From: Marshall Price on 3 May 2008 18:39
BoneLady wrote:
> On Apr 23, 6:12 pm, Ron Peterson <r...(a)shell.core.com> wrote:
>> On Apr 23, 10:51 am, BoneLady <srsuppor...(a)gmail.com> wrote:
>>
>>> Are you interested in an alternative to prescription drugs for
>>> osteoporosis? athttp://strontiumforbones.blogspot.com/. >
>> I don't believe that strontium is considered a nutrient and that makes
>> it difficult to recommend.
>>
>> And since strontium is more dense to xrays, it can cause misleading
>> BMD tests.
>>
>> The tests have only been done with strontium renelate which makes it
>> hard to conclude that strontium citrate would have the same action.
>>
>> --
>> Multiple clinical trials conducted since the 1950s using strontium gluconate,carbonate,lactate and chloride have attested to the efficacy of supplemental strontium in building strong bones. The ranelate studies are more recent. It is the elemental strontium itself that does the bone building. Strontium citrate has the advantage of better gastric tolerance.See my blog for links to some of the clinical studies. The person reading your dexa scan should make adjustments to the reading if you have been taking strontium. See http://www.osteopenia3.com/Strontium-dexa-scan.html.
> BoneLady at http://strontiumforbones.blogspot.com/
>

Say, BoneLady, if you could limit the length of your lines to 72
characters, it'd make life easier for some of us. I hate having to
fetch my mouse out of storage! :-)

--
Marshall Price of Miami
Known to Yahoo as d021317c
First  |  Prev  |  Next  |  Last
Pages: 1 2 3
Prev: Vitamin D lecture
Next: Could Strontium Citrate Contain Strontium-90?